Kevin Charles Gorman Sells 2,274 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Kevin Charles Gorman sold 2,274 shares of Neurocrine Biosciences stock in a transaction on Monday, February 10th. The stock was sold at an average price of $118.37, for a total value of $269,173.38. Following the sale, the director now directly owns 519,074 shares of the company’s stock, valued at $61,442,789.38. This represents a 0.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Kevin Charles Gorman also recently made the following trade(s):

• On Friday, January 31st, Kevin Charles Gorman sold 2,707 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $152.92, for a total value of $413,954.44.
• On Monday, January 27th, Kevin Charles Gorman sold 146,105 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $149.46, for a total value of $21,836,853.30.

Neurocrine Biosciences Trading Down 0.3 %

NASDAQ:NBIX opened at $116.87 on Friday. The stock has a market cap of $11.65 billion, a P/E ratio of 35.52 and a beta of 0.33. The stock’s 50-day moving average is $138.28 and its 200-day moving average is $130.92. Neurocrine Biosciences, Inc. has a 1-year low of $110.95 and a 1-year high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.45%. As a group, equities analysts forecast that Neurocrine Biosciences, Inc. will post 6.53 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on NBIX. Piper Sandler reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Neurocrine Biosciences in a research note on Monday, December 23rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Neurocrine Biosciences in a research note on Friday, February 7th. Deutsche Bank Aktiengesellschaft began coverage on Neurocrine Biosciences in a research note on Tuesday. They issued a “hold” rating and a $138.00 price target for the company. Canaccord Genuity Group dropped their price target on Neurocrine Biosciences from $172.00 to $163.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Finally, Guggenheim dropped their price target on Neurocrine Biosciences from $165.00 to $163.00 and set a “buy” rating for the company in a research note on Monday. Five research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $166.90.

Institutional Trading of Neurocrine Biosciences

Several institutional investors have recently added to or reduced their stakes in NBIX. Dodge & Cox boosted its holdings in Neurocrine Biosciences by 134.2% in the fourth quarter. Dodge & Cox now owns 3,016,425 shares of the company’s stock valued at $411,742,000 after acquiring an additional 1,728,605 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Neurocrine Biosciences in the fourth quarter valued at approximately $115,193,000. Wellington Management Group LLP boosted its holdings in Neurocrine Biosciences by 102.9% in the fourth quarter. Wellington Management Group LLP now owns 1,457,425 shares of the company’s stock valued at $198,939,000 after acquiring an additional 739,199 shares during the last quarter. Thrivent Financial for Lutherans boosted its holdings in Neurocrine Biosciences by 2,759.4% in the fourth quarter. Thrivent Financial for Lutherans now owns 737,772 shares of the company’s stock valued at $100,705,000 after acquiring an additional 711,970 shares during the last quarter. Finally, State Street Corp boosted its holdings in shares of Neurocrine Biosciences by 11.7% during the 3rd quarter. State Street Corp now owns 5,148,293 shares of the company’s stock worth $593,186,000 after buying an additional 539,936 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.